Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.

Clin Neurol Neurosurg

Department of Neurology, Istanbul University, Cerrahpasa Medical School, 34098 Istanbul, Turkey.

Published: June 2005

Objective: To assess and compare the disease severity, the treatment properties and the frequency of motor complications in the patients with Parkinson's disease (PD) having and not having REM sleep behavior disorder (RBD).

Patients And Methods: Based on chart review, patients with Parkinson's disease whose bed partners have reported prominent motor activity while dreaming were identified. Standard questionnaires assessing the presence of RBD have been addressed to these patients and their informants. Obtained data fulfilled clinical diagnostic criteria of probable RBD in 35 patients (RBD group) with the mean age at symptom onset was 61.8 years. Of them 77% were men. Clinical features of these patients concerning Hoehn-Yahr stage of PD, the severity of PD according to the Unified Parkinson's disease rating scale (UPDRS), the mean dose and duration of levodopa (LD) therapy, the presence of motor complications were compared with those of gender and age at PD-onset matched 35 PD patients without RBD (NRBD group).

Results: The mean values of PD duration, Hoehn-Yahr stage and UPDRS scores did not differ between groups. The duration of LD therapy was significantly longer in RBD group in comparison to NRBD group (6.2 years versus 3.05 years, respectively, P<0.005) and also mean actual dose of LD was higher (460.3 mg/day versus 320.3 mg/day respectively, P<0.02). The dose and duration of dopamine agonists did not differ between groups. In RBD group, wearing-off phenomenon was significantly common (P<0.01), its duration was longer (P<0.005), and LD-related dyskinesias were more frequent (P<0.01).

Conclusion: In the current study, when compared with NRBD group, the patients with RBD required higher doses of LD treatment at an earlier stage of PD which eventually led to motor complications. In these patients, dopaminergic treatment restored UPDRS scores, but did not prevent the occurrence of RBD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2004.09.021DOI Listing

Publication Analysis

Top Keywords

parkinson's disease
16
patients parkinson's
12
clinical features
8
features patients
8
behavior disorder
8
motor complications
8
patients rbd
8
rbd group
8
hoehn-yahr stage
8
patients
7

Similar Publications

Parkinson's disease (PD) is characterized by motor and non-motor symptoms, including olfactory dysfunction. Prior studies have shown that olfaction deteriorates with disease progression, however fluctuations in olfaction and related PD symptoms have been less explored. This study aimed to investigate correlations between changes in odor identification ability and PD symptoms.

View Article and Find Full Text PDF

Background: Tai Chi (TC) is widely acknowledged for its positive impact on improving motor function in older adults. Nevertheless, limited research has directly compared the effects of different TC styles on older adults with functional impairments.

Objective: This study aimed to assess the impact of different TC styles on motor function in older adults with functional impairments.

View Article and Find Full Text PDF

The anti-dyskinetic effect of the clinic-ready mGluRpositive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.

L-3,4-dihydroxyphenylalanine (L-DOPA) remains the main treatment for motor symptoms of Parkinson's disease (PD). However, chronic use is associated with the development of complications such as L-DOPA-induced dyskinesia. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of L-DOPA.

View Article and Find Full Text PDF

Assessing the Association Between Gadolinium-Based Contrast Agents and Parkinson Disease: Insights From the Korean National Health Insurance Service Database.

Invest Radiol

January 2025

From the Department of Radiology, Ansan Hospital, Korea University College of Medicine, Ansan, South Korea (C.K., C.K., Y.H.L.); Department of Urology, Ansan Hospital, Korea University College of Medicine, Ansan, South Korea (B.S.T.); and Department of Neurology, Ansan Hospital, Korea University College of Medicine, Ansan, South Korea (D.-Y.K.).

Objectives: This study aimed to investigate the association between the use of linear and macrocyclic gadolinium-based contrast agents (GBCAs) and the subsequent development of Parkinson disease (PD).

Methods: In this retrospective cohort study, data were extracted from the Korean National Health Insurance Service database, comprising 1,038,439 individuals. From this population, 175,125 adults aged 40 to 60 years with no history of brain disease were identified.

View Article and Find Full Text PDF

Editorial on: Confirmation of RAB32 Ser71Arg involvement in Parkinson's disease.

Mov Disord

January 2025

Department of Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!